Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.

NCT07320963 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: Chidamide
BIOLOGICAL: Toripalimab
DRUG: Anlotinib

Sponsor

Sun Yat-sen University

Collaborators

[object Object]
[object Object]